VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Aug. 4, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was […]
Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich’s Ataxia
CARY, N.C., April 5, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was […]
JAYPIRCA (pirtobrutinib), FDA Approved for Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Available at Biologics by McKesson
CARY, N.C., Feb. 14, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Feb. 10, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected […]
FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson
CARY, N.C., Dec. 22, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected […]
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
KRAZATI® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
CARY, N.C., Dec. 14, 2022 — Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, […]
ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson
CARY, N.C., December 12, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
Biologics by McKesson is now the Exclusive Specialty Pharmacy Provider of XERMELO (telotristat ethyl), an FDA Approved Therapy for Carcinoid Syndrome Diarrhea
CARY, N.C., July 25, 2022 —Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has […]
VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by […]